Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc. (NYSE: AORT)
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a prominent medical device company dedicated to developing elegant and straightforward solutions addressing the complex challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company offers a wide array of aortic-centric products, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, distributed in over 100 countries worldwide.
Recent Achievements and Financial Performance:
- For the third quarter of 2023, Artivion reported revenues of $87.9 million, marking a 14% increase year-over-year, with notable growth in aortic stent grafts and On-X mechanical heart valves.
- Completed enrollment in the PERSEVERE clinical trial, targeting PMA approval for the AMDS Hybrid Prosthesis by 2025, showcasing significant reductions in all-cause mortality and major adverse events.
- Announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and further optimize the capital structure, highlighting the company's strategic growth initiatives.
Product Innovation and Clinical Trials:
- The On-X Aortic Heart Valve Low INR post-market study demonstrated superior patient outcomes, significantly reducing major bleeding events compared to historic controls.
- Artivion's product portfolio includes innovative solutions like the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissections.
With a strong focus on clinical efficacy and market expansion, Artivion continues to be a pivotal player in the cardiac and vascular surgery market, striving to deliver life-saving products and technologies that improve patient outcomes.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery solutions, announced that it will release its first quarter 2023 financial results on May 4, 2023, post-market. A teleconference call and live webcast will follow at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin. Investors can access the teleconference by dialing 862-298-0702. The replay will be available within an hour post-event. This announcement emphasizes Artivion's ongoing commitment to transparency with its stakeholders regarding its financial performance. The company's innovative product lines, including aortic stent grafts and surgical sealants, aim to address complex cardiac challenges, positioning Artivion within the competitive landscape of over 100 countries globally.
Artivion, Inc. (NYSE: AORT) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 18, 2023 at 8:45 a.m. ET. The company's virtual fireside chat will focus on advancements in cardiac and vascular surgery for aortic diseases.
A live webcast will be available on Artivion's website, with an archived version accessible for 90 days. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for cardiac and vascular surgeons, offering products such as aortic stents, surgical sealants, On-X mechanical heart valves, and implantable human tissues, distributed in over 100 countries.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference. The virtual event is set for March 14, 2023, at 3:20 p.m. ET. A live webcast will be available on Artivion's website, with a 90-day archive post-event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic disease, offering products like aortic stents, surgical sealants, and On-X mechanical heart valves. The company operates in over 100 countries globally. For more information, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT) reported its fourth quarter and full-year 2022 results. The fourth quarter revenues were $79.4 million, flat year-over-year, but up 5% on a non-GAAP constant currency basis. For the full year, revenues reached $313.8 million, a 5% increase on a GAAP basis. Net income for Q4 2022 was $2.2 million compared to a net loss of $20.1 million in Q4 2021. The company anticipates 2023 revenue growth of 8.0% to 12%, with projected revenues between $331 million and $343 million. A CE mark for BioGlue was received, and confidence was noted for PMA approval for PerClot.
Artivion, Inc. (NYSE: AORT) announced its fourth-quarter and full-year 2022 financial results will be released on February 16, 2023, post-market. The Company will host a teleconference at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by Pat Mackin, Chairman and CEO. Interested parties can listen live by dialing 201-689-8261 or access the webcast through the Artivion website. A replay will be available shortly after the call. Artivion specializes in medical devices for aortic diseases, offering products in over 100 countries.
Artivion, Inc. (NYSE: AORT) announced participation in two investor conferences on November 16 and November 17, 2022. The management team will present at the Stifel 2022 Healthcare Conference on November 16 at 9:10 a.m. ET, with a live webcast available on their website. Additionally, they will hold one-on-one meetings at the Canaccord Genuity MedTech Forum on November 17. Artivion specializes in medical devices for aortic diseases and operates in over 100 countries.
Artivion, Inc. (NYSE: AORT) reported third-quarter 2022 revenue of $76.8 million, marking a 6% increase on a GAAP basis compared to Q3 2021. Non-GAAP constant currency revenue grew by 11%. Notable growth came from On-X, with a 17% GAAP and 19% non-GAAP increase. Internationally, revenue rose by 25% in Asia Pacific and 22% in Latin America. However, the company faced a net loss of $13.7 million compared to a profit in the prior year. The revenue outlook for 2022 has been narrowed to $313.0-$316.0 million, projecting 9%-10% growth. The company also anticipates FDA approvals for key products by year-end.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
What products does Artivion, Inc. offer?
Where is Artivion, Inc. headquartered?
What are some recent clinical achievements of Artivion?
What was Artivion's revenue growth in the third quarter of 2023?
How is Artivion addressing its debt maturities?
In how many countries does Artivion market its products?
What is the focus of Artivion's clinical trials?
What are the key products in Artivion's portfolio?
What are the benefits of the On-X Aortic Heart Valve?
When does Artivion expect to achieve PMA approval for the AMDS Hybrid Prosthesis?
